Inspire Investing’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Inspire Investing’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,915	Closed	-$410K	–	886
2024 Q4	$410K	Sell	4,915 -691	-12%	-$56.8K	0.05%	357
2024 Q3	$410K	Buy	5,606 +528	+10%	+$39.7K	0.04%	692
2024 Q2	$348K	Sell	5,078 -76	-1%	-$5.27K	0.04%	713
2024 Q1	$357K	Sell	5,154 -213	-4%	-$14.6K	0.04%	715
2023 Q4	$384K	Sell	5,367 -477	-8%	-$27.4K	0.04%	518
2023 Q3	$304K	Buy	5,844 +837	+17%	+$48.8K	0.04%	767
2023 Q2	$317K	Buy	5,007 +14	+0.3%	+$872	0.04%	438
2023 Q1	$270K	Buy	4,993 +538	+12%	+$26K	0.03%	762
2022 Q4	$236K	Buy	4,455 +8	+0.2%	+$401	0.03%	511
2022 Q3	$207K	Buy	+4,447	New	+$232K	0.03%	571

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Inspire Investing's ITCI Position: Q1 2025 in Review

Inspire Investing sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 4,915 shares — an estimated $410K sold.

Inspire Investing first reported a position in ITCI in Q3 2022 and held it in 10 quarters. The position peaked at $410K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Inspire Investing reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Inspire Investing sold 4,915 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $410K.
Inspire Investing first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 10 quarters.
Inspire Investing's Intra-Cellular Therapies Inc. position peaked at $410K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Inspire Investing's 13F filing for Q1 2025, filed 3 Jun 2025.